LifeVantage (NASDAQ:LFVN – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 0.700-0.800 for the period, compared to the consensus EPS estimate of 0.720. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $204.8 million.
LifeVantage Trading Down 3.8 %
Shares of LifeVantage stock traded down $0.51 during trading hours on Tuesday, reaching $12.98. 172,827 shares of the company’s stock were exchanged, compared to its average volume of 59,519. LifeVantage has a 52-week low of $4.20 and a 52-week high of $14.71. The company has a fifty day moving average of $10.68 and a 200-day moving average of $8.27. The firm has a market capitalization of $164.86 million, a price-to-earnings ratio of 46.36 and a beta of 0.84.
LifeVantage (NASDAQ:LFVN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.07). The business had revenue of $48.93 million during the quarter. LifeVantage had a return on equity of 27.85% and a net margin of 1.47%.
LifeVantage Announces Dividend
About LifeVantage
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Further Reading
- Five stocks we like better than LifeVantage
- How to invest in marijuana stocks in 7 steps
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- 3 Healthcare Dividend Stocks to Buy
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.